Ethics and the pharmaceutical industry

References

• Bodenheimer T. Uneasy alliance – clinical investigators and the pharmaceutical industry. New England Journal of Medicine 2000; 342: 1539–1544
   PubMed Web of Science ®Google Scholar
• Blumenthal D. Doctors and drug companies. New England Journal of Medicine 2004; 351: 1885–1890
   PubMed Web of Science ®Google Scholar
• Relman AS, Angell M. America's other drug problem. The New Republic 2002; 4: 3–41
   Google Scholar
• Kassirer J: On the Take: How America's Complicity with Big Business can Endanger your Health. New York: Oxford Press, 2005.
   Google Scholar
• Dyer A. Psychiatry as a profession. Psychiatric Ethics3rd edn, S Bloch, P Chodoff, S Green. Oxford University Press, Oxford 1999; 67–79
   Google Scholar
• Thompson DF. Understanding financial conflicts of interest. New England Journal of Medicine 1993; 329: 573–576
   PubMed Web of Science ®Google Scholar
• Hodges B. Interactions with the pharmaceutical industry. Canadian Medical Association Journal 1995; 153: 553–559
   Web of Science ®Google Scholar
• Sandberg WS, Carlos R, Sandberg EH, Roizen MF. The effect of educational gifts from pharmaceutical firms on medical students’ recall of company names or products. Academic Medicine 1997; 72: 916–918
   PubMed Web of Science ®Google Scholar
• Wazana A. Physicians and the pharmaceutical industry: is a gift ever just a gift?. Journal of the American Medical Association 2000; 283: 373–380
   PubMed Web of Science ®Google Scholar
• Dana J, Lowenstein G. A social science perspective on gifts to physicians from industry. New England Journal of Medicine 2003; 290: 252–255
   Google Scholar
• Spingarn R, Berlin J, Strom B. When pharmaceutical manufacturers’ employees present ground rounds, what do residents remember?. Academic Medicine 1996; 71: 86–88
   PubMed Web of Science ®Google Scholar
• McCormick BB, Tomlilnson G, Brill-Edwards P, Detsky AS. Effects of restricting contact between pharmaceutical company representatives and internal medicine residents on post-training attitudes and behavior. Journal of the American Medical Association 2001; 286: 1994–1999
   PubMed Web of Science ®Google Scholar
• Relman AS. Separating continuing education from pharmaceutical marketing. Journal of the American Medical Association 2001; 285: 2009–2012
   PubMed Web of Science ®Google Scholar
• Vergano D. Who's teaching the doctors? USA Today. 9 March 2000; D1.
   Google Scholar
• Berenson A. Drug files show maker promoted unapproved use. New York Times. 6 February 2007; A12.
   Google Scholar
• Moran M. Sharfstein challenges psychiatrists to help reform health system. Psychiatric News 2005; 40(12)4
   Google Scholar
• Wazana A, Primeau F. Ethical considerations in the relationship between physicians and the pharmaceutical industry. The Psychiatric Clinics of North America 2002; 25: 647–663
   PubMed Web of Science ®Google Scholar
• Halasz G. A symposium of attention deficit hyperactivity disorder (ADHD): an ethical perspective. Australian and New Zealand Journal of Psychiatry 2002; 36: 472–475
   PubMed Web of Science ®Google Scholar
• Berenson A. Eli Lilly said to play down risk of top pill. New York Times. 17 December 2006; A1.
   Google Scholar
• Kondro W. Drug company experts advised staff to withhold data about SSRI use in children. Canadian Medical Association Journal 2004; 170: 783–785
   PubMed Web of Science ®Google Scholar
• Lo B, Wolf L, Berkeley A. Conflict-of-interest policies for investigators in clinical trials. New England Journal of Medicine 2000; 343: 1616–1620
   PubMed Web of Science ®Google Scholar
• Blumenthal D, Gluck M, Louis KS, Wise D. Industrial support of university research in biotechnology. Science 1986; 231: 242–246
   PubMed Web of Science ®Google Scholar
• Blumenthal D, Causino N, Campbell E, Louis KS. Relationships between academic institutions and industry in the life sciences: an industry survey. New England Journal of Medicine 1996; 334: 368–373
   PubMed Web of Science ®Google Scholar
• Bekelman JE, Li Y, Gross CP. Scope and impact of financial conflicts of interest in biomedical research: a systematic review. Journal of the American Medical Association 2003; 289: 454–465
   PubMed Web of Science ®Google Scholar
• Blumenthal D, Campbell EG, Causino N, Louis KS. Participation of life-science faculty in research relationships with industry. New England Journal of Medicine 1996; 335: 1734–1739
   PubMed Web of Science ®Google Scholar
• Perlis R, Perlis C, Wu Y, Hwang C, Joseph M, Nierenberg A. Industry sponsorship and financial conflict of interest in the reporting of clinical trials in psychiatry. American Journal of Psychiatry 2005; 162: 1957–1960
   PubMed Web of Science ®Google Scholar
• Bero LA, Rennie D. Influences on the quality of published drug studies. International Journal of Technology Assessment in Health Care 1996; 12: 209–237
   PubMed Web of Science ®Google Scholar
• Melander H, Ahlqvist-Rastad J, Meijer G, Beermann B. Evidence b(i)ased medicine – selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications. British Medical Journal 2003; 326(7400)1171–1178
   PubMed Web of Science ®Google Scholar
• Angell M. The Truth About Drug Companies: How They Deceive Us and What To Do About It. Random House, New York 2004
   Google Scholar
• Congressional Budget Office Research and development in the pharmaceutical industry. Washington, DC: Congressional Budget Office Study, 2006.
   Google Scholar
• DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. Journal of Health Economics 2003; 22: 151–185
   PubMed Web of Science ®Google Scholar
• Carey B. Little difference found in schizophrenia drugs. New York Times. 20 September 2005; A1.
   Google Scholar
• Rawls J. A Theory of Justice. Harvard University Press, Cambridge, MA 1971
   Google Scholar
• Pear R. Drug companies increase spending in efforts to lobby congress and governments. New York Times. 1 June 2003; A33.
   Google Scholar
• The Institute of Medicine Committee on the Assessment of the US Drug Safety System. The Future of Drug Safety: Promoting and Protecting the Health of the Public. Washington, DC: Institute of Medicine of the National Academies, 2006.
   Google Scholar
• Altman D. The new Medicare prescription-drug legislation. New England Journal of Medicine 2004; 350: 9–10
   PubMedGoogle Scholar
• Mintzes B, Barer ML, Kravitz RL, et al. How does direct-to-consumer advertising (DTCA) affect prescribing? A survey in primary care environments with and without legal DCTA. Canadian Medical Association Journal 2003; 169(5)405–412
   PubMed Web of Science ®Google Scholar
• Lieberman J. Comparative effectiveness of antipsychotic drugs: commentary. Archives of General Psychiatry 2006; 63: 1069
   PubMed Web of Science ®Google Scholar
• Vedantam S. In Antipsychotics, Newer Isn't Better. Washington Post. 3 January 2006; A1.
   Google Scholar
• Rosack J. Lilly to pay up to $500 million to settle claims. New York Times. 4 January 2007; A12.
   Google Scholar
• Anonymous. Paxil Dispute Settled. Washington Post. 29 March 2006; D2.
   Google Scholar
• Anonymous. Glaxo to Pay $70 Million to Settle Suits on Drug Prices. New York Times. 11 August 2006; A12.
   Google Scholar
• Lavoie D. Schering-Plough agrees to plead guilty, pay fine. Washington Post. 30 August 2006; D3.
   Google Scholar
• Green S, Bloch S. An Anthology of Psychiatric Ethics. Oxford University Press, Oxford 2006
   Google Scholar
• Hundert EM. A model for ethical problem solving in medicine, with practical applications. American Journal Psychiatry 1987; 144: 839–846
   PubMedGoogle Scholar
• Bloch S, Green S. An ethical framework for psychiatry. British Journal Psychiatry 2006; 188: 7–12
   PubMed Web of Science ®Google Scholar
• Department of Health and Human Services, Office of Inspector General. Compliance Program for pharmaceutical Manufacturers. Federal Register 68, no. 86 (2003) 23731–23743.
   Google Scholar
• Brennan T, Rothman D, Blank L, et al. Health industry practices that create conflicts of interest: a proposal for academic medical centers. Journal of the American Medical Association 2006; 295: 429–433
   PubMed Web of Science ®Google Scholar
• Anonymous. MDs Tutored to Say No to Drug Companies. Washington Post. 3 November 2006, A14.
   Google Scholar
• Arno P, Davis M. Why don't we enforce existing drug price controls?. Tulane Law Review 2001; 75: 631–693
   Google Scholar
• Kaufman M Former FDA chief illegally held stocks. Washington Post. 17 October 2006, A19.
   Google Scholar